Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Influencer and podcast maven Claudia Oshry used Ozempic to kickstart a newfound wellness journey.

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.